Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

11 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours

ABSTRACT: Pancreatic neuroendocrine tumor (PanNET) is relatively infrequent but is nevertheless metastatic. Seeking to extend a new paradigm of personalized medicine, we performed an integrative analysis of transcriptomic (mRNA and microRNA) and mutational profiles and defined three clinically relevant human PanNET subtypes. Importantly, cross-species analysis revealed two of these three subtypes in a well-characterized, genetically engineered mouse model (RIP1-Tag2) of PanNET and its cell lines. Each subtype share similarities to distinct cell types in pancreatic neuroendocrine development, features are reflected in their metabolic profiles. Subtype-specific molecular signatures metabolites are proposed to identify these subtypes. RNA was extracted from fresh frozen archival patient PanNET samples and hybridized on Affymetrix GeneChip human Gene 1.0 ST arrays. The CEL files were processed using R based bioconductor and normalized values were obtained using RMA.

ORGANISM(S): Homo sapiens

SUBMITTER: Anguraj Sadanandam

PROVIDER: E-GEOD-73339 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours (tumor stages)

Project description:Pancreatic neuroendocrine tumor (PanNET) is relatively infrequent but is nevertheless metastatic. Seeking to extend a new paradigm of personalized medicine, we performed an integrative analysis of transcriptomic (mRNA and microRNA) and mutational profiles and defined three clinically relevant human PanNET subtypes. Importantly, cross-species analysis revealed two of these three subtypes in a well-characterized, genetically engineered mouse model (RIP1-Tag2) of PanNET and its cell lines. Each subtype share similarities to distinct cell types in pancreatic neuroendocrine development, features are reflected in their metabolic profiles. Subtype-specific molecular signatures metabolites are proposed to identify these subtypes. Gene expression data from different stages of RIP1-TAG2 genetically engineered PanNET mouse model RT2 mouse PanNET tumors, liver metastases, normal, hyperplastic, and angiogenic islets were dissected out or isolated. RNA was extracted and hybridized on Affymetrix GeneChip Mouse Gene 1.0 ST arrays. The CEL files were processed using aroma.affymetrix.

2015-10-30 | E-GEOD-73514 | biostudies-arrayexpress

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours (tumor stages)

2015-10-30 | GSE73514 | GEO

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours (miRNA)

2015-10-30 | GSE73367 | GEO

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours

2015-10-30 | GSE73339 | GEO

A cross species and multi-omics (including metabolomics) analysis in pancreatic neuroendocrine tumours (miRNA)

Project description:Pancreatic neuroendocrine tumor (PanNET) is relatively infrequent but is nevertheless metastatic. Seeking to extend a new paradigm of personalized medicine, we performed an integrative analysis of transcriptomic (mRNA and microRNA) and mutational profiles and defined three clinically relevant human PanNET subtypes. Importantly, cross-species analysis revealed two of these three subtypes in a well-characterized, genetically engineered mouse model (RIP1-Tag2) of PanNET and its cell lines. Each subtype share similarities to distinct cell types in pancreatic neuroendocrine development, features are reflected in their metabolic profiles. Subtype-specific molecular signatures metabolites are proposed to identify these subtypes. Total RNA was extracted from fresh frozen archival patient PanNET samples and hybridized on Agilent microRNA arrays. All normalization methods were performed on the Total Gene Signal from Agilent "GeneView" data files in R, an open source statistical scripting language (http://www.r-project.org). Except for VSN, data were log2 transformed after adding a small constant such that the smallest value of the data set was 1 before taking the log. Scaling normalization was performed by dividing each array by its mean signal intensity and then by rescaling to the global mean intensity of all arrays. Quantile normalization was performed using the "normalize.quantiles" function from R package "affy" from the Bioconductor project (http://www.bioconductor.org).

2015-10-30 | E-GEOD-73367 | biostudies-arrayexpress

Combined deletion of MEN1, ATRX and PTEN triggers pancreatic neuroendocrine tumorigenesis in mice

Project description:Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of tumors that exhibit an unpredictable and broad spectrum of clinical presentations and biological aggressiveness. Surgical resection is still the only curative therapeutic option for localized PanNET but the majority of patients are diagnosed at an advanced and metastatic stage with limited therapeutic options. Key factors limiting the development of new therapeutics are the extensive heterogeneity of PanNETs and the lack of appropriate clinically relevant models. In that context, genomic sequencing of human PanNETs revealed recurrent mutations and structural alterations in several tumor suppressors. Here, we demonstrated that combined loss of MEN1, ATRX, and PTEN, tumor suppressors commonly mutated in human PanNETs, triggers pancreatic neuroendocrine tumorigenesis in mice. Histopathological evaluation and gene expression analyses of the developed tumors confirm the presence of PanNET hallmarks and significant overlap in gene expression patterns found in human disease. Thus, we postulate that the presented novel genetically defined neuroendocrine-specific tumor mouse is the first clinically relevant immunocompetent in vivo PanNET model.

2024-04-17 | GSE248606 | GEO

LC-MS of Human Blood of Pancreatic neuroendocrine tumors

Project description:Pancreatic Neuroendocrine tumors are challenging to diagnose and often detected at advanced stages due to lack of specific and sensitive biomarkers. This study utilized proteomics as a valuable approach for cancer biomarker discovery, therefore, mass spectrometry-based proteomic profiling was conducted on plasma samples from 12 subjects (3 controls; 9 PanNET patients) to identify potential proteins capable of effectively distinguish PanNET from healthy controls. 13.2% of proteins were uniquely identified in PanNET, while 60% were commonly expressed in PanNET and controls. 17 proteins exhibiting significant differential expression between PanNET and controls were identified with downstream analysis.

2024-01-26 | PXD045045 | Pride

Expression profiles of Rb-deficient islet cells in mouse

Project description:Pancreatic neuroendocrine tumors (PanNET) were classified into grades (G) 1-3 by the World Health Organization in 2017, but the precise mechanisms of PanNET initiation and progression have remained unclear. In this study, we used a genetically engineered mouse model to investigate the mechanisms of PanNET formation. Although pancreas-specific deletion of the Rb gene (Pdx1-Cre;Rbf/f) in mice did not affect pancreatic exocrine cells, the α-cell/β-cell ratio of islet cells was decreased at 8 months of age. During long-term observation (18-20 months), mice formed well-differentiated PanNET with a Ki67-labeling index of 2.7%. In contrast, pancreas-specific induction of a p53 mutation (Pdx1-Cre;Trp53R172H) had no effect on pancreatic exocrine and endocrine tissues, but simultaneous induction of a p53 mutation with Rb gene deletion (Pdx1-Cre;Trp53R172H;Rb f/f) resulted in the formation of aggressive PanNET with a Ki67-labeling index of 24.7% over the short-term (4 months). In Pdx1-Cre;Trp53R172H;Rb f/f mice, mRNA expression of Pten and Tsc2, negative regulators of the mTOR pathway, significantly decreased in the islet cells, and activation of the mTOR pathway was confirmed in subsequently formed PanNET. Thus, by manipulating Rb and p53 genes, we established a multistep progression model from dysplastic islet to indolent PanNET and aggressive metastatic PanNET in mice. These observations suggest that Rb and p53 have distinct roles in the development of PanNET.

2020-06-17 | GSE152582 | GEO

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

Project description:Pancreatic neuroendocrine tumors (PanNETs) account for 1-3% of all neoplasms of the pancreas. Epigenetic changes seem to be the main drivers of PanNET tumorigenesis. Indeed, the most frequent mutated genes in PanNETs are DAXX (Death domain associated protein 6), ATRX (Transcriptional Regulator ATRX) and MEN1 (menin 1), which are all involved in epigenetic regulation. The objective of the project is to study the epigenetic changes undergoing in PanNETs. Specifically, we aimed at investigating whether do exist biologically important epigenetic differences in PanNET, useful for a clinically relevant classification.

2022-11-30 | E-MTAB-11962 | biostudies-arrayexpress

Genome-wide methylation profiling of sporadic Pancreatic Neuroendocrine Tumors

2022-11-30 | E-MTAB-11965 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data